Kengreal is called Kengrexal in Europe.
Information about Kengreal (Cangrelor)
Kengreal (cangrelor) is an intravenous antiplatelet medication designed to inhibit platelet aggregation. It is a direct P2Y12 receptor antagonist, used primarily in a clinical setting to reduce the risk of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI).
Product Highlights
- Reducing the risk of myocardial infarction (heart attack), stent thrombosis, and urgent coronary revascularization in patients undergoing PCI.
- Used in conjunction with other antiplatelet therapies like aspirin and clopidogrel.
Key Ingredient
Key Benefits
- Immediate effect on platelet inhibition, which is crucial during PCI procedures.
- The effects dissipate quickly after stopping the infusion, allowing for flexible management of antiplatelet therapy.
- Compared to some oral antiplatelet medications, Kengreal may have a favorable safety profile regarding bleeding complications.
Direction of Use
- Administered intravenously; dosing is typically initiated before PCI and continued for a specific duration based on clinical protocols.
- Continuous infusion may be required, with careful monitoring of patient response and platelet function.
Safety Concerns
- Increased risk of major and minor bleeding events.
- Monitor for potential drops in blood pressure during administration.
- Watch for signs of hypersensitivity or anaphylaxis.
Avoid Kengreal (Cangrelor) If
- History of allergic reactions to cangrelor or any components of the formulation.
- Conditions such as gastrointestinal bleeding or bleeding disorders that may exacerbate bleeding risks.
- Caution in patients with severe renal impairment due to altered pharmacokinetics.
